{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:32:09Z","timestamp":1777926729076,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":3932,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.ymthe.2005.08.016","type":"journal-article","created":{"date-parts":[[2005,11,30]],"date-time":"2005-11-30T20:42:03Z","timestamp":1133383323000},"page":"221-228","source":"Crossref","is-referenced-by-count":346,"title":["Phase I\/II Trial of Intravenous NDV-HUJ Oncolytic Virus in Recurrent Glioblastoma Multiforme"],"prefix":"10.1016","volume":"13","author":[{"given":"Arnold I.","family":"Freeman","sequence":"first","affiliation":[]},{"given":"Zichria","family":"Zakay-Rones","sequence":"additional","affiliation":[]},{"given":"John M.","family":"Gomori","sequence":"additional","affiliation":[]},{"given":"Eduard","family":"Linetsky","sequence":"additional","affiliation":[]},{"given":"Linda","family":"Rasooly","sequence":"additional","affiliation":[]},{"given":"Evgeniya","family":"Greenbaum","sequence":"additional","affiliation":[]},{"given":"Shira","family":"Rozenman-Yair","sequence":"additional","affiliation":[]},{"given":"Amos","family":"Panet","sequence":"additional","affiliation":[]},{"given":"Eugene","family":"Libson","sequence":"additional","affiliation":[]},{"given":"Charles S.","family":"Irving","sequence":"additional","affiliation":[]},{"given":"Eithan","family":"Galun","sequence":"additional","affiliation":[]},{"given":"Tali","family":"Siegal","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2005.08.016_bib1","first-page":"1","article-title":"Biology and treatment of malignant glioma","volume":"27","author":"Prados","year":"2000","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ymthe.2005.08.016_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/jns.1998.88.1.0001","article-title":"Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973-1991","volume":"88","author":"Davis","year":"1998","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.ymthe.2005.08.016_bib3","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1200\/JCO.1999.17.8.2572","article-title":"Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials","volume":"17","author":"Wong","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2005.08.016_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1750-3639.2003.tb00006.x","article-title":"Targeted molecular therapy of GBM","volume":"13","author":"Mischel","year":"2003","journal-title":"Brain Pathol."},{"key":"10.1016\/j.ymthe.2005.08.016_bib5","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrd1380","article-title":"Development of novel targeted therapies in the treatment of malignant glioma","volume":"3","author":"Rich","year":"2004","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.ymthe.2005.08.016_bib6","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.2741\/976","article-title":"Oncolytic viruses for the therapy of brain tumors and other solid malignancies: a review","volume":"8","author":"Fulci","year":"2003","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ymthe.2005.08.016_bib7","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/89901","article-title":"Replication-selective virotherapy for cancer: biological principles, risk management and future directions","volume":"7","author":"Kirn","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2005.08.016_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1023\/B:NEON.0000003651.97832.6c","article-title":"Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas","volume":"65","author":"Shah","year":"2003","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.ymthe.2005.08.016_bib9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/B:NEON.0000003653.45635.32","article-title":"Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses","volume":"65","author":"Vecil","year":"2003","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.ymthe.2005.08.016_bib10","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.ymthe.2004.07.021","article-title":"A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting","volume":"10","author":"Chiocca","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.08.016_bib11","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.gt.3301205","article-title":"Conditionally replicating herpes simplex virus mutant, G207, for the treatment of malignant glioma: results of a phase I trial","volume":"7","author":"Markert","year":"2000","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2005.08.016_bib12","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1006\/mthe.2000.0200","article-title":"Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus","volume":"2","author":"Todo","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.08.016_bib13","first-page":"2462","article-title":"Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme","volume":"63","author":"Phuong","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2005.08.016_bib14","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1517\/14712598.4.8.1307","article-title":"Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus","volume":"4","author":"Thorne","year":"2004","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2005.08.016_bib15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/jnci\/93.12.903","article-title":"Reovirus as an oncolytic agent against experimental human malignant gliomas","volume":"93","author":"Wilcox","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ymthe.2005.08.016_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1386-6532(99)00072-4","article-title":"Newcastle disease virus (NDV): brief history of its oncolytic strains","volume":"16","author":"Sinkovics","year":"2000","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.ymthe.2005.08.016_bib17","unstructured":"National Cancer Institute on Newcastle disease virus as a treatment for cancer, online at http:\/\/www.nci.nih.gov\/cancerinfo\/pdq\/cam\/NDV."},{"key":"10.1016\/j.ymthe.2005.08.016_bib18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/BF01212880","article-title":"Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells","volume":"122","author":"Bar-Eli","year":"1996","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2005.08.016_bib19","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/1097-0142(196507)18:7<863::AID-CNCR2820180714>3.0.CO;2-V","article-title":"Newcastle disease virus as an antineoplastic agent","volume":"18","author":"Cassel","year":"1965","journal-title":"Cancer"},{"key":"10.1016\/j.ymthe.2005.08.016_bib20","first-page":"6017","article-title":"Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy","volume":"54","author":"Lorence","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2005.08.016_bib21","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/jnci\/86.16.1228","article-title":"Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy","volume":"86","author":"Lorence","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ymthe.2005.08.016_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0304-3835(01)00617-6","article-title":"Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration","volume":"172","author":"Phuangsab","year":"2001","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ymthe.2005.08.016_bib23","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0022-4804(92)90310-V","article-title":"Newcastle disease virus selectively kills human tumor cells","volume":"52","author":"Reichard","year":"1992","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.ymthe.2005.08.016_bib24","first-page":"945","article-title":"Antitumor effects of Newcastle disease virus in vivo: local versus systemic effects","volume":"18","author":"Schirrmacher","year":"2001","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ymthe.2005.08.016_bib25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF01198099","article-title":"The effect of a mesogenic and a lentogenic Newcastle disease virus strain on Burkitt lymphoma Daudi cells","volume":"121","author":"Tzadok-David","year":"1995","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2005.08.016_bib26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF02987752","article-title":"A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate","volume":"9","author":"Cassel","year":"1992","journal-title":"Med. Oncol. Tumor Pharmacother."},{"key":"10.1016\/j.ymthe.2005.08.016_bib27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/B:NEON.0000021735.85511.05","article-title":"MTH-68\/H oncolytic viral treatment in human high-grade gliomas","volume":"67","author":"Csatary","year":"2004","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.ymthe.2005.08.016_bib28","first-page":"618","article-title":"Overview of phase I studies of intravenous administration of PV701, an oncolytic virus","volume":"5","author":"Lorence","year":"2003","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.08.016_bib29","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2002.08.042","article-title":"Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers","volume":"20","author":"Pecora","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2005.08.016_bib30","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1200\/JCO.2004.09.038","article-title":"Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit","volume":"22","author":"Steiner","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2005.08.016_bib31","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1054\/bjoc.2000.1316","article-title":"A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse","volume":"83","author":"Yung","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2005.08.016_bib32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1008382516636","article-title":"Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse","volume":"12","author":"Brada","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2005.08.016_bib33","first-page":"1602","article-title":"Gene expression-based classification of malignant gliomas correlates better with survival than histological classification","volume":"63","author":"Nutt","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2005.08.016_bib34","series-title":"Newcastle Disease Virus\u2014An Evolving Pathogen","first-page":"205","author":"Hanson","year":"1964"},{"key":"10.1016\/j.ymthe.2005.08.016_bib35","series-title":"Manual of Standards for Diagnostic Tests and Vaccines","year":"2000"},{"key":"10.1016\/j.ymthe.2005.08.016_bib36","first-page":"85","article-title":"Human tumor cell infection by Newcastle disease virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis","volume":"21","author":"Washburn","year":"2002","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ymthe.2005.08.016_bib37","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00262-004-0602-0","article-title":"Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory","volume":"54","author":"Schirrmacher","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2005.08.016_bib38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/ni0704-699","article-title":"RIGging an antiviral defense\u2014It's in the CARDs","volume":"5","author":"Levy","year":"2004","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2005.08.016_bib39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/viro.2002.1413","article-title":"Induction of interferon-\u03b1 and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin\u2013neuraminidase but not F protein of Newcastle disease virus","volume":"297","author":"Zeng","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2005.08.016_bib40","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1084\/jem.192.2.219","article-title":"Natural interferon alpha\/beta-producing cells link innate and adaptive immunity","volume":"192","author":"Kadowaki","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2005.08.016_bib41","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00109-002-0339-1","article-title":"Stimulation of human natural interferon-alpha response via paramyxovirus hemagglutinin lectin\u2013cell interaction","volume":"80","author":"Zeng","year":"2002","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ymthe.2005.08.016_bib42","first-page":"673","article-title":"Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-alpha responses by viral protein or dsRNA","volume":"23","author":"Fournier","year":"2003","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ymthe.2005.08.016_bib43","first-page":"363","article-title":"Newcastle disease virus activates macrophages for anti-tumor activity","volume":"16","author":"Schirrmacher","year":"2000","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ymthe.2005.08.016_bib44","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/intimm\/8.4.491","article-title":"Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa B","volume":"8","author":"Umansky","year":"1996","journal-title":"Int. Immunol."},{"key":"10.1016\/j.ymthe.2005.08.016_bib45","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2307\/1590839","article-title":"Elevated virulence of Newcastle disease virus strains following serial passages in kidney cells in vitro","volume":"33","author":"Slosaris","year":"1989","journal-title":"Avian Dis."},{"key":"10.1016\/j.ymthe.2005.08.016_bib46","doi-asserted-by":"crossref","first-page":"320","DOI":"10.4049\/jimmunol.88.3.320","article-title":"Application of a microtechnique to viral serological investigations","volume":"88","author":"Sever","year":"1962","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2005.08.016_bib47","first-page":"493","article-title":"A simple method of estimating 50 percent end points","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Hyg."},{"key":"10.1016\/j.ymthe.2005.08.016_bib48","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","article-title":"Accelerated titration designs for phase I clinical trials in oncology","volume":"89","author":"Simon","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ymthe.2005.08.016_bib49","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2005.08.016_bib50","series-title":"Newcastle Disease Vaccines: Their Production and Use","author":"Allan","year":"1978"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001605015704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001605015704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T17:42:45Z","timestamp":1683308565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001605015704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S1525001605015704"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2005.08.016","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}